A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.
A small randomized trial demonstrated that novel maintenance immunotherapy(VIGIL) provided durable disease control in homologous repair proficient (HRP) ovarian cancer.